79074-03-6

Usage

Uses

Used in Peptide Synthesis:
2-(benzyloxycarbonylamino)-4-hydroxybutanoic acid is used as a building block for peptide synthesis for its ability to protect the amino group during peptide assembly and subsequent deprotection under mild conditions.
Used in Pharmaceutical Industry:
2-(benzyloxycarbonylamino)-4-hydroxybutanoic acid is used as a potential therapeutic agent for various diseases, including cancer and inflammatory disorders, due to its potential anti-inflammatory and anti-cancer properties, as well as its role in regulating immune responses.

Upstream product

• 1927-25-9 DL-Homoserine 
• 501-53-1 benzyl chloroformate 
• 498-19-1 L-(-)-homoserine 

Downstream Products

• 55596-51-5 2-Benzyloxycarbonylamino-4-hydroxy-butyric acid 4-nitro-benzyl ester 
• 109164-77-4 3-[2-(tert-Butyl-dimethyl-silanyloxy)-ethyl]-1-(4-methoxy-benzyl)-piperazine-2,5-dione 
• 109164-76-3 [[2-Benzyloxycarbonylamino-4-(tert-butyl-dimethyl-silanyloxy)-butyryl]-(4-methoxy-benzyl)-amino]-acetic acid ethyl ester 
• 109392-76-9 6,8-bis(p-methoxybenzyl)-2-methylene-6,8-diazabicyclo-<2.2.2>octane-5,7-dione 
• 109392-80-5 1,4-bis-(p-methoxybenzyl)-3-(formylmethyl)2,5-piperazinedione 
• 109392-81-6 1,4-bis(p-methoxybenzyl)-3-(2,3-epoxypropyl)-2,5-piperazinedione 
• 109392-82-7 6,8-bis(p-methoxybenzyl)-2-(hydroxymethyl)-6,8-diazabicyclo<2.2.2>octane-5,7-dione 
• 109392-79-2 1,4-bis(p-methoxybenzyl)-3-(2-hydroxyethyl)-2,5-piperazinedione 
• 109392-75-8 7,9-bis(p-methoxybenzyl)-7,9-diazabicyclo<3.2.2>non-2-ene-6,8-dione 
• 109392-83-8 7,9-bis(p-methoxybenzyl)-3-hydroxy-7,9-diazabicyclo<3.2.2>nonane-6,8-dione 
• 109392-78-1 3-[2-(tert-Butyl-dimethyl-silanyloxy)-ethyl]-1,4-bis-(4-methoxy-benzyl)-piperazine-2,5-dione 
• 116536-02-8 n=5 
• 116506-92-4 n=4 
• 116506-91-3 n=3 

Relevant academic research and scientific papers

KCNT1 INHIBITORS AND METHODS OF USE

The present invention is directed to, in part, compounds and compositions useful for preventing and/or treating a neurological disease or disorder, a disease or condition relating to excessive neuronal excitability, and/or a gain-of-function mutation in a gene (e.g., KCNT1). Methods of treating a neurological disease or disorder, a disease or condition relating to excessive neuronal excitability, and/or a gain-of-function mutation in a gene such as KCNT1 are also provided herein.

Synthesis and in vitro enzyme activity of aza, oxa and thia derivatives of bacterial cell wall biosynthesis intermediates

Mechanism based inhibitors of diaminopimelate aminotransferase (DAP-AT) were designed using knowledge of its substrate specificity and mechanism. Synthesis of thiolester and amide substrate analogues was achieved prior to in vitro inhibition studies, but ester analogues proved too unstable to isolate. Thia substrate analogues showed no inhibitory properties, but the aza substrate analogue 12a showed reversible inhibition vs. DAP-AT and time dependent inhibition in the absence of the natural substrate 4. Substrate analogue 12a is thefirst example of an amide inhibitor of PLP dependent enzymes. Antibiotic properties of 12a were also briefly assessed.

SOLID-PHASE SYNTHESIS OF A NATURALLY OCCURING β-(1-5)-LINKED D-GALACTOFURANOSYL HEPTAMER CONTAINING THE ARTIFICAL LINKAGE ARM L-HOMOSERINE

The glycosyl donor 2,3-di-O-benzoyl-5-O-levulinoyl-6-O-pivaloyl-β-D-Galactofuranosyl chloride and properly-protected L-homoserine covalently bound to polystyrene were employed for the stereoregular formation of a D-galactofuranosyl heptamer containing β-(1-5)-interglycosidic bond and a β-linked L-homoserine via a solid phase approach